OHSU Knight Cancer Institute shared a post on X:
“Innovation has been limited over the past 2 decades, making these peer-reviewed data particularly important for patients with intermediate to high-risk localized prostate cancer.”
Dr. Mark Garzotto on new Prostate Cancer research.
Title: Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
Author: Hannah Clarke.
Other articles about OHSU on OncoDaily.